CKB News Archive



  • 2020
    • September
      • CKB UPDATE! CORE and BOOST now include transcripts with version numbers. Questions? Feel free to contact us at ckbsupport@jax.org.
  • 2020
    • July
      • New FDA approval for Atezolizumab plus Cobimetinib and Vemurafenib for patients with BRAF V600-positive advanced melanoma! Find more information on this in CKB CORE. Need up-to-date information on other FDA drug approvals? Consider a CKB BOOST subscription, which includes full access to all drugs and their FDA approvals, along with related content!
  • 2020
    • May
      • Check out CKB's new cancer variant visual navigation! Learn more here.
  • 2020
    • January
      • CKB CORE now offers content for RSPO3, POLE, FANCA, and DOT1L, but removes EGFR, PTEN, TP53, and MET. However, these genes are always accessible with a CKB BOOST subscription!
  • 2019
    • October
      • Have a question about CKB or want to learn more about it? Then check out The Scoop on CKB!
  • 2019
    • July
      • CKB BOOST now has AMP/CAP/ASCO evidence level coding!
  • 2018
    • November
      • Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit ckbhome.jax.org and sign-up for CKB BOOST.
  • 2017
    • October
      • Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic (PMID: 28402162). Limited free copies available; request your copy at ckbsupport@jax.org.